Author Guidelines
About Pharminsight
Pharminsight is an open-access platform dedicated to sharing expert perspectives, opinions, white papers, case studies, and translational insights from professionals across pharmaceuticals, biotechnology, healthcare, regulatory sciences, manufacturing, investment, and innovation ecosystems.
Our objective is to create a credible forum where experienced professionals can share practical knowledge, lessons learned, emerging trends, challenges, and solutions that can help advance the life sciences industry.
Pharminsight is not a scientific journal. Submissions are evaluated based on relevance, originality, clarity, practical impact, and quality of insight rather than academic novelty alone.
Types of Contributions
Perspective Articles: expert viewpoints on emerging technologies, industry trends, regulatory developments, scientific challenges, manufacturing strategies, market evolution, or future opportunities. Recommended length: 1,000–2,000 words.
Opinion Articles: thought-provoking commentary on current issues affecting the pharmaceutical and biotechnology sectors. Recommended length: 800–1,500 words.
White Papers: comprehensive analyses of strategic, scientific, technical, regulatory, manufacturing, or policy-related topics. Recommended length: 2,000–5,000 words.
Industry Problem Statements: description of a significant industry challenge together with proposed solutions, frameworks, or recommendations. Recommended length: 1,000–2,500 words.
Case Studies: lessons learned from product development, technology implementation, process optimization, regulatory submissions, commercialization, or organizational transformation. Recommended length: 1,500–3,000 words.
Submission Requirements
All submissions should include:
- Title: clear and concise.
- Author information: full name, designation, organization, country, email address, and LinkedIn profile (optional).
- Abstract: 100–200 words summarizing the key message.
- Keywords: 3–8 keywords.
- Main content: organized using appropriate headings and subheadings.
- Key takeaways: 3–5 concise bullet points highlighting the major insights.
- References: where appropriate, references to published literature, reports, regulations, guidance documents, or credible sources.
Content Expectations
We encourage authors to:
- Share practical experiences
- Present evidence-based opinions
- Highlight lessons learned
- Discuss challenges and opportunities
- Propose solutions and recommendations
- Offer future outlooks
We discourage:
- Promotional content
- Product marketing
- Excessive corporate branding
- Literature summaries without original insight
- AI-generated generic content lacking expert interpretation
- Confidential or proprietary information
Figures, Tables, and Visuals
Authors may submit figures, infographics, tables, illustrations, and process flows. Authors are responsible for obtaining permissions for any third-party content. All visuals should include captions and source information where applicable.
Disclosure and Transparency
Authors must disclose employment affiliations, consulting relationships, financial interests, sponsorships, and potential conflicts of interest. The editorial team may request additional disclosures when necessary.
Editorial Review Process
All submissions undergo editorial assessment for relevance, accuracy, clarity, originality, professional conduct, and industry value.
Submissions may be accepted, accepted with revisions, returned for major revisions, or declined. Editorial decisions are final.
Publication and Copyright
Authors retain ownership of their original work while granting Pharminsight the right to publish, distribute, archive, and promote the content.
Minor editorial modifications may be made for formatting, readability, grammar, and consistency. Substantive changes will be communicated to authors before publication.
AI-Assisted Writing
Authors may use AI-assisted tools for language improvement and drafting support. However:
- Authors remain fully responsible for accuracy.
- AI-generated content must be reviewed and validated.
- Fabricated references, data, or claims are strictly prohibited.
Code of Conduct
Pharminsight promotes respectful, evidence-based, and constructive dialogue. Submissions containing offensive, discriminatory, defamatory, misleading, or unethical content will not be considered.
Our Editorial Philosophy
We value practical wisdom as much as scientific rigor.
The most impactful submissions are often those that combine technical expertise, real-world experience, and actionable recommendations that help move the life sciences ecosystem forward.